Page 87 - Read Online

Toniutto et al. Hepatoma Res 2020;6:50 I http://dx.doi.org/10.20517/2394-5079.2020.40 Page 17 of 21

hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35-43.
12. Al-Ameri AAM, Wei X, Wen X, Wei Q, Guo H, et al. Systematic review: risk prediction models for recurrence of hepatocellular
carcinoma after liver transplantation. Transpl Int 2020;33:697-712.
13. Shah SA, Tan JC, McGilvray ID, Cattral MS, Levy GA, et al. Does microvascular invasion affect outcomes after liver transplantation for
HCC? A histopathological analysis of 155 consecutive explants. J Gastrointest Surg 2007;11:464-71.
14. Zhang X, Li J, Shen F, Lau WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of
hepatocellular carcinoma. J Gastroenterol Hepatol 2018;33:347-54.
15. Jonas S, Bechstein WO, Steinmuller T, Herrmann M, Radke C, et al. Vascular invasion and histopathologic grading determine outcome
after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001;33:1080-6.
16. Costentin CE, Bababekov YJ, Zhu AX, Yeh H. Is it time to reconsider the Milan Criteria for selecting patients with hepatocellular
carcinoma for deceased-donor liver transplantation? Hepatology 2019;69:1324-36.
17. Herrero JI, Sangro B, Quiroga J, Pardo F, Herraiz M, et al. Influence of tumor characteristics on the outcome of liver transplantation
among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl 2001;7:631-6.
18. Roayaie S, Frischer JS, Emre SH, Fishbein TM, Sheiner PA, et al. Long-term results with multimodal adjuvant therapy and liver
transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002;235:533-9.
19. Kneteman NM, Oberholzer J, Al Saghier M, Meeberg GA, Blitz M, et al. Sirolimus-based immunosuppression for liver transplantation in
the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004;10:1301-11.
20. Silva M, Moya A, Berenguer M, Sanjuan F, Lopez-Andujar R, et al. Expanded criteria for liver transplantation in patients with cirrhosis
and hepatocellular carcinoma. Liver Transpl 2008;14:1449-60.
21. Fan J, Zhou J, Xu Y, Qiu SJ, Wu ZQ, et al. Indication of liver transplantation for hepatocellular carcinoma: Shanghai Fudan Criteria.
Zhonghua Yi Xue Za Zhi 2006;86:1227-31.
22. Fan J, Yang GS, Fu ZR, Peng ZH, Xia Q, et al. Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center
experience in Shanghai, China. J Cancer Res Clin Oncol 2009;135:1403-12.
23. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-
expanded criteria based on preoperative imaging. Am J Transplant 2007;7:2587-96.
24. American College of Radiology. Liver Imaging Reporting and Data System (LI-RADS). Available from: https://www.acr.org/Clinical-
Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2017. [Last accessed on 21 Jul 2020]
25. Lee S, Kim SS, Roh YH, Choi JY, Park MS, et al. Diagnostic performance of CT/MRI Liver imaging reporting and data system v2017 for
hepatocellular carcinoma: a systematic review and meta-analysis. Liver Int 2020;40:1488-97.
26. Cillo U, Vitale A, Bassanello M, Boccagni P, Brolese A, et al. Liver transplantation for the treatment of moderately or well-differentiated
hepatocellular carcinoma. Ann Surg 2004;239:150-9.
27. Sotiropoulos GC, Malago M, Molmenti E, Paul A, Nadalin S, et al. Liver transplantation for hepatocellular carcinoma in cirrhosis: is
clinical tumor classification before transplantation realistic? Transplantation 2005;79:483-7.
28. Shah SA, Tan JC, McGilvray ID, Cattral MS, Cleary SP, et al. Accuracy of staging as a predictor for recurrence after liver transplantation
for hepatocellular carcinoma. Transplantation 2006;81:1633-9.
29. Cuccurullo V, Di Stasio GD, Mazzarella G, Cascini GL. Microvascular Invasion in HCC: the molecular imaging perspective. Contrast
Media Mol Imaging 2018;2018:9487938.
30. Yaprak O, Acar S, Ertugrul G, Dayangac M. Role of pre-transplant 18F-FDG PET/CT in predicting hepatocellular carcinoma recurrence
after liver transplantation. World J Gastrointest Oncol 2018;10:336-43.
31. Sweeney MJ, Ashmore J, Morris HP, Weber G. Comparative biochemistry hepatomas. Iv. isotope studies of glucose and fructose
metabolism in liver tumors of different growth rates. Cancer Res 1963;23:995-1002.
32. Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma
with FDG-PET. J Nucl Med 1995;36:1811-7.
33. Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, et al. The role of (18)F-FDG-PET imaging for the selection of liver transplantation
candidates among hepatocellular carcinoma patients. Liver Transpl 2006;12:1655-60.
34. Lee SD, Kim SH. Role of positron emission tomography/computed tomography in living donor liver transplantation for hepatocellular
carcinoma. Hepatobiliary Surg Nutr 2016;5:408-14.
35. Kornberg A, Kupper B, Tannapfel A, Buchler P, Krause B, et al. Patients with non-[18 F]fludeoxyglucose-avid advanced hepatocellular
carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation. Liver Transpl 2012;18:53-61.
36. Lin CY, Liao CW, Chu LY, Yen KY, Jeng LB, et al. Predictive value of 18F-FDG PET/CT for vascular invasion in patients with
hepatocellular carcinoma before liver transplantation. Clin Nucl Med 2017;42:e183-e87.
37. Bailly M, Venel Y, Orain I, Salame E, Ribeiro MJ. 18F-FDG PET in liver transplantation setting of hepatocellular carcinoma: predicting
histology? Clin Nucl Med 2016;41:e126-9.
38. Ahn SY, Lee JM, Joo I, Lee ES, Lee SJ, et al. Prediction of microvascular invasion of hepatocellular carcinoma using gadoxetic acid-
enhanced MR and (18)F-FDG PET/CT. Abdom Imaging 2015;40:843-51.
39. Takada Y, Kaido T, Shirabe K, Nagano H, Egawa H, et al. Significance of preoperative fluorodeoxyglucose-positron emission tomography
in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: a Japanese multicenter study. J
Hepatobiliary Pancreat Sci 2017;24:49-57.
40. Lee SD, Kim SH, Kim SK, Kim YK, Park SJ. Clinical Impact of 18F-Fluorodeoxyglucose positron emission tomography/computed
tomography in living donor liver transplantation for advanced hepatocellular carcinoma. Transplantation 2015;99:2142-9.